Saturday, October 20, 2018, 9:00 a.m. - 12:00 p.m. Central time
Letters of Intent (LOI) for phase 0 and phase 1 clinical trials are an essential part of the clinical trial protocol development process. A LOI is the first step in the application process that precedes the submission of a trial protocol. Without a successful LOI, the effort to write a clinical trial protocol will be wasted.
At the 2017 ASTRO Immunotherapy Workshop, we held our first Letter of Intent Writing Workshop, meant to educate our members on how to plan and design successful clinical trials and write the all-important Letter of Intent in order to start such a trial.
Charles Kunos, MD, National Cancer Institute
Jeffrey Buchsbaum, MD, National Cancer Institute
Dow-Chung Chi, Food and Drug Administration
Friday, July 27, 2018, 1:00 p.m. - 5:00 p.m. Eastern time